Answers are grounded in this paper and cite their sources.
Proteolysis-targeting chimeras (PROTACs) represent a revolutionary therapeutic modality that hijacks the ubiquitin–proteasome system (UPS) to achieve selective degradation of pathogenic proteins. Unlike conventional inhibitors, PROTACs can eliminate previously "undruggable" targets, offering unique advantages such as high potency and the potential to overcome drug resistance. Despite advances in the treatment of kidney diseases, a common limitation is the lack of effective therapies that can precisely target the core protein drivers of renal pathology. This review aims to systematically elucidate the theoretical rationale for applying PROTAC technology to address key challenges in nephrology, comprehensively summarize its preclinical progress across a range of kidney diseases, and thoroughly analyze the core obstacles from molecular design to clinical translation. With its innovative strategy of mechanistically eliminating disease-causing proteins, PROTAC technology holds the potential to revolutionize the treatment of kidney disease and usher in a new era of precision medicine.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: